Antitumor agent-145

Cat. No.: HY-162348: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Antitumor agent-145 (Compound Ir5) is a tumor inhibitor with remarkable fluorescence and mitochondrial targeting, which exerts anti-cancer effects by inducing necroptosis and activating the necroptosis-related immune response.

For research use only. We do not sell to patients.

Antitumor agent-145 Chemical Structure

CAS No. : 2983120-65-4

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Antitumor agent-145 (Compound Ir5) (48 h) could effectively reduce the cell viability of BEL-7402/DDP cells with IC₅₀ value of 0.49 μM and a resistance coefficient (RF) of 1.04. No obvious cytotoxicity Antitumor agent-145^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Antitumor agent-145 (Compound Ir5) (1.5 or 3.0 mg/kg, intravenous injection, every other day for 21 days) significantly reduced tumor volume and inhibited tumor metastasis in BALB/c mice. Antitumor agent-145 does not cause significant liver and kidney dysfunction in mouse models^[1].
Antitumor agent-145 (1.5 or 3.0 mg/kg, intravenous injection, every other day for 21 days) BEL-7402/DDP tumor xenograft models can significantly inhibit the growth and metastasis of CDDP resistant tumors without causing obvious tissue damage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice
Dosage:	NaCl, CDDP (3 mg/kg), Ir5 (1.5 mg/kg), and Ir5 (3 mg/kg)
Administration:	every other day for 21 days
Result:	The tumor volume in BALB/c mice was significantly reduced, and there was no significant difference in the weight of major organs.

Animal Model:	BEL-7402/DDP tumor xenograft models
Dosage:	1.5 mg/kg or 3 mg/kg
Administration:	every 2 days for 21 days
Result:	The results revealed that Ir5 significantly decreases the tumor volume, with an inhibition rate of tumor growth (IRT) of 40.0% at a dose of 1.5 mg/kg and 58.1% at a dose of 3 mg/kg, compared to only 10.1% in the CDDP group. No obvious tissue injury.

Molecular Weight

873.06

Formula

C₄₄H₃₄IrN₅OS

CAS No.

2983120-65-4

SMILES

OC1=C(C2=CC=CC=C2C=C1)/C=[N]3N=C(N(C)C)[S-][Ir+3]\345([N]6=C(C7=C(C=C6)C=CC=C7)C8=CC=CC=[C-]85)[N]9=C(C%10=C(C=C9)C=CC=C%10)C%11=CC=CC=[C-]%114

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Li, Wenjuan et al. “Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response.” Journal of medicinal chemistry vol. 67,5 (2024): 3843-3859. [Content Brief]